Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset
Introduction
Case reports of akathisia have appeared since 1960, when Kruse published three case reports on patients who developed “muscular restlessness” after treatment with phenothiazines (Kruse, 1960). Akathisia is probably the most common and one of the more distressing of the movement disorders associated with antipsychotic drugs (Barnes, 1989). This syndrome consists of a subjective feeling of inner restlessness and the urge to move, as well as objective components (rocking while standing or sitting, lifting feet as if marching on the spot and crossing and uncrossing the legs while sitting). Little is known about the prevalence of akathisia and its risk factors in real-world schizophrenia to date (Rummel-Kluge et al., 2012).
A recent meta-analysis based on 7 randomized controlled trials (N = 998) suggested that second-generation antipsychotics (SGA) outperformed first-generation (FGA) regarding akathisia onset (Zhang et al., 2013). However, another meta-analysis highlighted that studies using scale-derived data for akathisia assessment (Barnes, 1989) were scant (Rummel-Kluge et al., 2012). Moreover, patients included in clinical trials are not always representative of real world patients, especially regarding co-administered medications. Patients with schizophrenia are often administered antipsychotic polytherapy (Correll and Gallego, 2012, Rajan and Clarke, 2013, Young et al., 2015), antidepressants, anxiolytics (Paton et al., 2000), and anticholinergic drugs (Dixon et al., 2001). All these drugs may influence akathisia. Antipsychotic polytherapy has been associated with higher extra-pyramidal side effects including akathisia (Young et al., 2015). Antidepressive agents, especially Selective Serotonin Reuptake Inhibitors (SSRIs), were also described to be associated with increased akathisia (Lane, 1998). Conversely, benzodiazepines (Lima et al., 2002) and anticholinergic drugs (Miller and Fleischhacker, 2000) were suggested as a potent treatment for acute akathisia, though with weak evidence. Most of the evidence is based on akathisia following treatment onset, but studies on akathisia in community-dwelling patients with schizophrenia are scarce to date (see Nyhuis et al., 2010).
The main objective of this study was to determine the prevalence of akathisia and to determine the risk factors and the treatments associated with akathisia in a non-selected community-dwelling sample of patients with schizophrenia.
Section snippets
Study population
The FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia; Schürhoff et al., 2015) cohort is based on a French national network of 10 Schizophrenia Expert Centers (Bordeaux, Clermont-Ferrand, Colombes, Créteil, Grenoble, Lyon, Marseille, Montpellier, Strasbourg, Versailles), set up by a scientific cooperation foundation in France, the FondaMental Foundation (www.fondation-fondamental.org) and created by the French Ministry of Research in order to create a platform that links
Results
Data on akathisia was available for 372 patients with schizophrenia (N = 291) or schizoaffective disorder (N = 81) enrolled in the FACE-SZ cohort and all these patients were included in this study. Table 1 shows demographical and clinical characteristics of the sample. Twenty-one patients were examined in Bordeaux (5.7%), 42 in Clermont-Ferrand (11.3%), 33 in Colombes (8.9%), 92 in Créteil (24.7%), 25 in Grenoble (6.7%), 17 in Lyon (4.6%), 27 in Marseille (7.3%), 30 in Montpellier (8.1%), 39 in
Discussion
Our major findings may be summarized as follows: the global prevalence of akathisia was 18.5% in our community-dwelling sample of patients with schizophrenia. Antipsychotic polytherapy (which included 30.4% of our sample) was associated with a higher risk of akathisia, independently of factors considered to have an influence on akathisia such as the daily-administered dose of antipsychotics or the co-administration of SSRI. Patients taking SGA were at lower risk of akathisia than those taking
Conflicts of interest
None declared.
Contributors
F. Berna and G. Fond wrote the first complete draft of the manuscript, L. Boyer, F. Berna and G. Fond performed the statistical analyses, D. Misdrahi and P-M. Llorca provided substantial modification to the final manuscript. All authors were involved in the collection of the data and approved the final manuscript.
Role of Funding Source
This work was funded by AP-HP (Assistance Publique des Hôpitaux de Paris), Fondation Fondamental (RTRS Santé Mentale), by the Investissements d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01, and by INSERM (Institut National de la Santé et de la Recherche Médicale).
Acknowledgments
We express all our thanks to the nurses, and to the patients who were included in the present study. We thank Hakim Laouamri, and his team (Stéphane Beaufort, Seif Ben Salem and Karmène Souyris) for the development of the FACE-SZ computer interface, data management and quality control. We also thank Sarah King for proofreading the manuscript.
References (48)
- et al.
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder
Schizophr. Res.
(2008) - et al.
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial
Neurol. Clin.
(2011) - et al.
Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice
Psychiatr. Clin. N. Am.
(2012) - et al.
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period
Schizophr. Res.
(2005) - et al.
Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia
Eur. Neuropsychopharmacol.
(2005) - et al.
Characteristics and clinical correlates of restless legs syndrome in schizophrenia
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2007) - et al.
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Lancet
(2009) - et al.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis
Lancet
(2003) - et al.
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment
Schizophr. Res.
(2008) - et al.
A national network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap
Eur. Psychiatry
(2015)
Diagnostic and statistical manual of mental disorders, revised fourth edition (DSM- IV-TR). Vol
A rating scale for drug-induced akathisia
Br. J. Psychiatry
Akathisia variants and tardive dyskinesia
Arch. Gen. Psychiatry
Chronic restlessness with antipsychotics
Am. J. Psychiatry
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy
Acta Psychiatr. Scand.
The significance of age of onset for schizophrenia
Schizophr. Bull.
Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders
Psychiatr. Serv.
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
BMC Psychiatry
Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2
The pharmacologic treatment of neuroleptic-induced akathisia
J. Clin. Psychopharmacol.
Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia
Psychiatr. Serv.
Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons
J. Psychopharmacol.
Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia
Br. J. Psychiatry
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
World J. Biol. Psychiatry
Cited by (40)
Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort
2021, Progress in Neuro-Psychopharmacology and Biological PsychiatryConfirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort
2020, Progress in Neuro-Psychopharmacology and Biological PsychiatryImplications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia
2019, Nursing Clinics of North AmericaValidation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryMachine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Further studies should determine if implementing clozapine in SZ patients with aggressiveness might improve the risk of psychotic relapse. The use of first-generation antipsychotics has also not been found to be associated with higher risk of psychotic relapse, despite potential lower efficacy and increased extrapyramidal and addictive side-effects (and therefore potential withdrawal) (Berna et al., 2015; Mallet et al., 2017). This is consistent with the results of a previous prospective study suggesting that extrapyramidal symptoms were not associated with time to relapse (Robinson et al., 1999).
Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :No comparable data is available to date, in other homeless populations or in non-homeless populations with SZ or BD. Previous studies carried out in housed SZ subjects have shown high rates of potentially inappropriate antidepressant and anxiolytic prescriptions, but not in a so important manner (Berna et al., 2015; Fond et al., 2017a, 2015; Fond et al., 2018). These results should therefore be replicated in other samples to confirm that this high rate is due to the homeless status.